Anti-infective Agents : Quinolones
IAVEL1 “Avelox infusion sol’n” 1.6 mg/ml; 250 ml/vial
IMOFA1 “Mofacin infusion sol’n” 1.746 mg/ml; 250 ml/bot
OAVEL1 “Avelox FC tablet” 400 mg/tab
適應症：用於治療成人（18歲以上）感受性細菌引起的感染症，包括上呼吸道及下呼吸道感染（急性鼻竇炎、慢性支氣管炎的急性惡化、社區性肺炎），皮膚和軟組織的感染，複雜腹腔內感染（包括多種細菌感染症）。
Usual dose: 400 mg ORALLY or IV infusion over 60 minutes once every 24 hours.
Dose adjustment:
renal impairment: no dose adjustment is necessary.
hepatic impairment: no dose adjustment recommended for mild, moderate, or severe hepatic insufficiency
geriatric: no dosage adjustment is necessary.
hemodialysis, peritoneal dialysis: no dosage adjustment is necessary
Contraindication:
hypersensitivity to moxifloxacin or any quinolone antibiotic.
Precaution:
cardiovascular: QT-interval prolongation has been reported; avoid use in patients with known QT prolongation
neurologic: CNS disorders (eg, severe cerebral arteriosclerosis, epilepsy) and conditions that lower the seizure threshold; increased risk for CNS events and seizures
Adverse effect:
Common: diarrhea, nausea,headache, dizziness, dry eyes.
Serious: prolonged QT interval, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, sizure.
Adverse effect: diarrhea, nausea, dizziness, headache.
健保使用規範：(91/2/1、92/11/1、94/3/1、97/9/1、105/8/1)
限用於成人(18歲以上)之下列感染症：
1.慢性支氣管炎的急性惡化、社區性肺炎、複雜性腹腔內感染。
2.急性鼻竇炎或複雜性皮膚和軟組織感染，因抗藥性細菌感染及病情需要，經感染科醫師會診確認需要使用者。